Inflammatory markers in gynecologic oncology patients hospitalized with COVID-19 infection

Smith, Maria; Lara, Olivia D.; O’Cearbhaill, Roisin E.; Knisely, Anne; McEachron, Jennifer; Gabor, Lisa; Carr, Caitlin; Blank, Stephanie V.; Prasad-Hayes, Monica; Frey, M.K.; Jee, Justin; Fehniger, Julia; Wang, Yuyan; Lee, Yi-Chun; Isani, Sara; Wright, Jason D.; Pothuri, Bhavana

doi:10.1016/j.ygyno.2020.09.036

Cited by 8 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…33,34 A decision was taken to include the study with the later date of publication. 34 Twenty-eight studies were included for meta-analysis; these included patients from Asia (three studies), 29,35,36 the Americas (10 studies), 5,[37][38][39][40][41][42][43][44][45] Europe (13 studies), 9,34,[46][47][48][49][50][51][52][53][54][55][56] and multinational registries (two studies). 6,57 The 28 studies that reported mortality in cancer patients with COVID-19 admitted to the ICU included a total of 1,276 patients, with dates of recruitment ranging from January 23 to June 11, 2020.…”

Section: Resultsmentioning

confidence: 99%

“…Fattizzo et al 47 Gonfiotti et al 48 Malard et al 51 Martin-Moro et al 49 Grasselli et al 34 Lee et al 46 Joharatnam-Hogan et al 52 Lamure et al 53 Shah et al 9 Passamonti et al 50 Haase et al 54 Garcia Suarez et al 55 Lievre et al 56 Subgroup Europe (I 2 = 51.61% , P = .016) Krause et al 42 Gupta et al 5 Robilotti et al 37 Mehta et al 38 Lara et al 39 Lunski et al 43 Luo et al 40 Singh et al 41 de Melo et al 45 Smith et al 44 Subgroup Americas (I 2 = 86.88% , P = .000)…”

Section: Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Mortality in Cancer Patients With COVID-19 Who Are Admitted to an ICU or Who Have Severe COVID-19: A Systematic Review and Meta-Analysis

Nadkarni

Vijayakumaran

Gupta

et al. 2021

JCO Global Oncology

View full text Add to dashboard Cite

PURPOSE There are scarce data to aid in prognostication of the outcome of critically ill cancer patients with COVID-19. In this systematic review and meta-analysis, we investigated the mortality of critically ill cancer patients with COVID-19. METHODS We searched online databases and manually searched for studies in English that reported on outcomes of adult cancer patients with COVID-19 admitted to an intensive care unit (ICU) or those with severe COVID-19 between December 2019 and October 2020. Risk of bias was assessed by the Modified Newcastle-Ottawa Scale. The primary outcome was all-cause mortality. We also determined the odds of death for cancer patients versus noncancer patients, as also outcomes by cancer subtypes, presence of recent anticancer therapy, and presence of one or more comorbidities. Random-effects modeling was used. RESULTS In 28 studies (1,276 patients), pooled mortality in cancer patients with COVID-19 admitted to an ICU was 60.2% (95% CI, 53.6 to 6.7; I2 = 80.27%), with four studies (7,259 patients) showing higher odds of dying in cancer versus noncancer patients (odds ratio 1.924; 95% CI, 1.596 to 2.320). In four studies (106 patients) of patients with cancer and severe COVID-19, pooled mortality was 59.4% (95% CI, –39.4 to 77.5; I2 = 72.28%); in one study, presence of hematologic malignancy was associated with significantly higher mortality compared with nonhematologic cancers (odds ratio 1.878; 95% CI, 1.171 to 3.012). Risk of bias was low. CONCLUSION Most studies were reported before the results of trials suggesting the benefit of dexamethasone and tocilizumab, potentially overestimating mortality. The observed mortality of 60% in cancer patients with COVID-19 admitted to the ICU is not prohibitively high, and admission to the ICU should be considered for selected patients (registered with PROSPERO, CRD42020207209).

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Studiesmentioning

confidence: 99%

Mortality in Cancer Patients With COVID-19 Who Are Admitted to an ICU or Who Have Severe COVID-19: A Systematic Review and Meta-Analysis

Nadkarni

Vijayakumaran

Gupta

et al. 2021

JCO Global Oncology

View full text Add to dashboard Cite

show abstract

“…[ 29 ] A multicenter retrospective study of 84 gynecological cancer patients found that CRP levels were significantly elevated in patients with severe infections (median 142.0 mg/L, IQR 62.4–217.1 vs median 62.3 mg/L, IQR 13.0–159.1; P = .02). [ 30 ] Most of these studies focused on Alpha strains. In this study, we did not analyze the association between CRP and severe pneumonia due to the low critical illness rate and mortality of Omicron.…”

Section: Discussionmentioning

confidence: 99%

Association between serum C-reactive protein (CRP) and Omicron variant COVID-19 pneumonia in cancer patients: A multicenter cross-sectional study at the end of 2022 in China

Che,

Zeng,

Hong

et al. 2024

Medicine

View full text Add to dashboard Cite

Cancer patients with COVID-19 have a higher infection rate and mortality rate than non-cancer patients. However, there are few studies on the correlation between the serum C-reactive protein (CRP) and cancer patients with COVID-19. This study aims to investigate the association between serum CRP and the incidence of COVID-19 pneumonia in cancer patients at the end of 2022 in China. This cross-sectional study with a retrospective cohort between December 2022 and February 2023 assessed cancer patients complicated with COVID-19 infection in 2 Chinese institutions. Logistic regression analyses were used to compute Odds ratio (OR) and 95%CIs for the association between serum CRP and the incidence of COVID-19 pneumonia in cancer patients. A total of 213 cancer patients with COVID-19 were enrolled. Eighty-six patients (40.4%) developed COVID-19 pneumonia, among which 23 patients (10.8%) progressed to severe cases. Univariate Logistic regression showed that high CRP levels were found to be an unfavorable predictor of COVID-19 outcomes (OR = 17.9, 95%CI: 7.3, 43.6; P < .001). In the multivariate analysis, high CRP levels were associated with a higher incidence rate of COVID-19 pneumonia (OR = 9.8, 95%CI: 2.2, 43.8; P = .003). In the multivariate logistic regression model and smooth curve fitting, we found a correlation between CRP and COVID-19 pneumonia. The serum CRP was associated with the incidence of Omicron variant COVID- 19 pneumonia in cancer patients. Hence, cancer patients with high CRP level maybe need for timely computer tomography examination and more aggressive treatment.

show abstract

“…With the spread and severity of the infection and the lack of control of virulence factors in the host, one of the main outcomes is the patient's death. (Upadhyay et al, 2020;Smith et al, 2020).…”

Section: Cytokine Stormmentioning

confidence: 99%

“…Individuals with more than one comorbidity tend to have a more severe prognosis and greater risk of death (Fakhroo et al, 2021). Despite all the studies related to the predictive role of biomarkers on poor prognosis in SARS-CoV-2 infection, it is known that, given the changes in the immune system and the inflammatory response of patients with chronic diseases, the association of biomarkers in this specific group is not fully elucidated, requiring further studies to understand the causal relationship entirely (Smith et al, 2020).…”

Section: Cytokine Stormmentioning

confidence: 99%

Can the exacerbated synthesis of inflammatory markers in COVID-19 impair the response to treatments in patients with coronavirus?

Cavalcante

Santos

Braga

et al. 2022

RSD

View full text Add to dashboard Cite

In addition to chronic diseases and empirical therapies against COVID-19, other factors are responsible for the high mortality rate associated with COVID-19. The objective of this study was to verify whether the exacerbated synthesis of inflammatory markers resulting from COVID-19 could compromise patients with coronavirus. The bibliographic research was performed in the Pubmed, LILACS, and SciELO databases between December 2020 and July 2021. For this study, the terms "COVID-19," "Biomarkers," "SARS-COV-2," and “Coronavirus 2019" are in advanced mode to gather the best evidence for the proposal of this manuscript. In the present construct, it is argued that COVID-19 increases the susceptibility of patients to a high stage of inflammation, increasing the virulence factors of the virus and its dissemination through the human body, where the synthesis of inflammatory factors plays a crucial role in the worsening of the cases. The virulence of the virus can be decreased by correcting the synthesis of these inflammatory markers, as it can prevent a less ineffective immune response and even increase the resistance of patients. Consequently, clinical trials in this direction should be carried out from the perspective of modulating responses at the molecular level, to find out how they work and how the underexpression of inflammatory cytokines may reduce the aggravation of patients with coronavirus.

show abstract

Inflammatory markers in gynecologic oncology patients hospitalized with COVID-19 infection

Cited by 8 publications

References 34 publications

Mortality in Cancer Patients With COVID-19 Who Are Admitted to an ICU or Who Have Severe COVID-19: A Systematic Review and Meta-Analysis

Mortality in Cancer Patients With COVID-19 Who Are Admitted to an ICU or Who Have Severe COVID-19: A Systematic Review and Meta-Analysis

Association between serum C-reactive protein (CRP) and Omicron variant COVID-19 pneumonia in cancer patients: A multicenter cross-sectional study at the end of 2022 in China

Can the exacerbated synthesis of inflammatory markers in COVID-19 impair the response to treatments in patients with coronavirus?

Contact Info

Product

Resources

About